Edge Rankings

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Telomir Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:TELO | Benzinga

Q: What sector and industry does Telomir Pharmaceuticals (TELO) operate in?

Telomir Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Explore Telomir Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for TELO.

Open	$2.07
Close	$2.15
Volume / Avg.	182.16K / 187.00K
Day Range	$2.01 - $2.15
52 Wk Range	1.87 - 8.40
Market Cap	$64.29M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	44
Short Interest	11.09%
Days to Cover	13.55

Recent News

EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder

Telomir-1 boosted telomere length, restored weight and muscle, and cut oxidative stress in a preclinical Werner Syndrome animal model.

Vandana Singh

EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND

Telomir Pharma (NASDAQ: TELO) secured $3M in equity financing from Bayshore Trust, its largest shareholder, at $3 per share (18% premium). It also has a $5M credit line. It has 2 innovative drug candidates targeting aging and infections, with promising preclinical results.

Anusuya Lahiri

Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows

Telomir-1 shows potential in oncology and age-related diseases, with new findings on its role in tumor suppression and chemotherapy toxicity reduction.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Open	$2.07
Close	$2.15
Volume / Avg.	182.16K / 187.00K
Day Range	$2.01 - $2.15
52 Wk Range	1.87 - 8.40
Market Cap	$64.29M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	44
Short Interest	11.09%
Days to Cover	13.55

About Telomir Pharmaceuticals Inc

Sector

Health Care

Industry

Pharmaceuticals

Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Telomir Pharmaceuticals (TELO) stock?

You can purchase shares of Telomir Pharmaceuticals (NASDAQ:TELO) through any online brokerage.

View our list of the best stock brokerages

Who are Telomir Pharmaceuticals (TELO) competitors?

Other companies in Telomir Pharmaceuticals’s space includes: Cumberland (NASDAQ:CPIX), Iterum Therapeutics (NASDAQ:ITRM), Universe Pharmaceuticals (NASDAQ:UPC), SCYNEXIS (NASDAQ:SCYX) and Nutriband (NASDAQ:NTRB).

What is the forecast, or price target, for Telomir Pharmaceuticals (TELO) stock?

There is no analysis for Telomir Pharmaceuticals to provide a consensus price target.

What is the current price for Telomir Pharmaceuticals (TELO)?

The stock price for Telomir Pharmaceuticals (NASDAQ: TELO) is $2.16 last updated June 6, 2025 at 6:26 PM EDT.

Does Telomir Pharmaceuticals (TELO) pay a dividend?

There are no upcoming dividends for Telomir Pharmaceuticals.

When is Telomir Pharmaceuticals (NASDAQ:TELO) reporting earnings?

Telomir Pharmaceuticals’s Q2 earnings are confirmed for Tuesday, August 12, 2025.

Is Telomir Pharmaceuticals (TELO) going to split?

There is no upcoming split for Telomir Pharmaceuticals.

What sector and industry does Telomir Pharmaceuticals (TELO) operate in?

Telomir Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Comments

Telomir Pharmaceuticals Stock Price, Quotes and Forecasts

Telomir Pharmaceuticals (TELO) Forecast